Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

This study has been completed.
Sponsor:
Collaborator:
Ibermutuamur M.A.T.E.P.S
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00717119
First received: July 14, 2008
Last updated: September 12, 2008
Last verified: July 2008

July 14, 2008
September 12, 2008
April 2008
Not Provided
Total work leave time [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00717119 on ClinicalTrials.gov Archive Site
  • GI complications [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]
  • Direct medical costs [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.
Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

Retrospective cohort study to evaluate the effect of the association of PPIs with NSAIDs in work leave time.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Data base of patients with work leave due to a sprain of ankle

Sprain of Ankle
Not Provided
1
Patients with sprain of ankle treated with NSAID
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6356
August 2008
Not Provided

Inclusion Criteria:

  • Work leave due to a sprain of ankle

Exclusion Criteria:

  • (none)
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00717119
NIS-GES-DUM-2008/3
No
Mónica Tafalla/MD, PhD, AstraZeneca Pharmaceuticals
AstraZeneca
Ibermutuamur M.A.T.E.P.S
Study Director: Javier N Rivero, MSc Epidemiology Unit. AstraZeneca
AstraZeneca
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP